Pricing Log in Create free account

Gain Therapeutics, Inc. (GANX) vs iBio, Inc. (IBIO)

Gain Therapeutics, Inc. and iBio, Inc. are both Biotechnology companies. Gain Therapeutics, Inc. and iBio, Inc. are of similar size ($44.4M and $41.9M). Gain Therapeutics, Inc. grew revenue faster over the last twelve months: 18.4% against −66.6%. Across the 14 metrics below, iBio, Inc. leads on 11 and Gain Therapeutics, Inc. on 3.

Valuation

Metric GANX IBIO Biotechnology median
P/E n/m n/m 10.60
P/S 219.56 115.62 9.40
P/B 3.80 0.91 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.25 0.66
EV/Sales 154.32 (12.78) 9.02
Earnings yield (50.00%) (45.33%) (32.88%)
Free cash flow yield (44.25%) (31.04%) (23.13%)

Profitability

Metric GANX IBIO Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (268.30%) (65.70%) (51.96%)
Return on assets (159.22%) (54.04%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GANX IBIO Biotechnology median
Revenue growth (TTM) 18.36% (66.55%) 6.76%
EPS growth (last fiscal year) 31.46% 81.71% 29.88%
Revenue growth, 5-year CAGR 21.79% (42.83%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GANX IBIO Biotechnology median
Debt to equity 0.03 0.00 0.00
Current ratio 4.36 7.85 4.97
Net debt to EBITDA 1.10 2.57 1.01

Dividend

Metric GANX IBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GANX IBIO Biotechnology median
Market cap 41.91m 44.43m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack